Soluble markers of viral rebound and post-treatment HIV control

Leila B. Giron, Alexander O. Pasternak, Mohamed Abdel-Mohsen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of reviewWe focus on the different classes of biological molecules measurable in easily accessible bodily fluids that have the potential to serve as biomarkers for the HIV post-treatment controller (PTC) phenotype and/or the timing of viral rebound after stopping antiretroviral therapy (ART).Recent findingsVarious viral components and host factors measurable in body fluids can play crucial roles in understanding and predicting the PTC phenotype. We review recent findings linking viral components, the quantitative and qualitative features of antibodies (including autologous HIV-specific antibodies), markers of inflammation and tissue damage, other host proteins (including hormones such as sex hormones), as well as metabolites, extracellular vesicles, and cell-free DNA to HIV control post-ART interruption. Several of these molecules can or have the potential to predict the time and probability of viral rebound after stopping ART and are biologically active molecules that can directly or indirectly (by modulating immune pressures) impact the size and activity of HIV reservoirs during and post-ART interruption.SummaryA comprehensive model combining multiple markers is needed to predict the PTC phenotype. This model can be leveraged to predict and understand the PTC phenotype, which can guide novel curative interventions to replicate this phenotype in post-treatment non-controllers.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalCurrent Opinion in HIV and AIDS
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2025

Funding

M.A.-M. is funded by Bill & Melinda Gates Foundation and the NIH grants (R01AI165079, R01NS117458, R01DK123733, R01AG062383, and P30 AI 045008). M.A.-M. and L.B.G. are members of the investigation team of the NIH-funded BEAT-HIV Martin Delaney Collaboratory to cure HIV-1 infection (UM1AI164570). A.O.P. is funded by the Dutch Medical Research Council (ZonMw), grant no. 09120011910035.

Keywords

  • HIV
  • post-treatment controllers
  • soluble biomarkers
  • viral rebound

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology

Fingerprint

Dive into the research topics of 'Soluble markers of viral rebound and post-treatment HIV control'. Together they form a unique fingerprint.

Cite this